Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Compounds, formulations, and methods for treating or preventing inflammatory skin disorders|
|Abstract:||In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.|
|Inventor(s):||DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)|
|Assignee:||Galderma Laboratories, L.P. (Fort Worth, TX)|
|Filing Date:||Feb 25, 2013|
|Claims:||1. A method of treating an inflammatory skin disorder and symptoms associated therewith, comprising topically administering to the skin of a patient in need of such treatment a composition comprising: a therapeutically effective amount of brimonidine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein the inflammatory skin disorder is not rosacea. |
2. The method according to claim 1, wherein the at least one compound is administered in an amount sufficient to decrease blood flow through the small arteries or arterioles of the skin of the patient.
3. The method according to claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions.
4. The method according to claim 1, wherein the composition acts locally in the skin of the patient.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.